Daniel Scotcher
Manchester University
H-index: 14
North America-United States
Top articles of Daniel Scotcher
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Facing the facts of altered plasma protein binding: Do current models correctly predict changes in fraction unbound in special populations? | Journal of Pharmaceutical Sciences | Jokha Al-Qassabi Shawn Pei Feng Tan Patcharapan Phonboon Aleksandra Galetin Amin Rostami-Hodjegan | 2024/2/28 |
Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation | Nihan Izat Jayaprakasam Bolleddula Armina Abbasi Lionel Cheruzel Robert S Jones | 2023/12/1 | |
Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease | Clinical Pharmacology & Therapeutics | Shawn Pei Feng Tan Marie‐Emilie Willemin Jan Snoeys Hong Shen Amin Rostami‐Hodjegan | 2023/12 |
Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats | Pharmaceutics | Nicola Melillo Daniel Scotcher J Gerry Kenna Claudia Green Catherine DG Hines | 2023/3 |
Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc receptor (FcRn) in human tissues and implications for pharmacokinetic … | European Journal of Pharmaceutical Sciences | Jill Barber Zubida M Al-Majdoub Narciso Couto Martyn Howard Yasmine Elmorsi | 2023/3/1 |
Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease | Clinical Pharmacology & Therapeutics | Hiroyuki Takita Daniel Scotcher Xiaoyan Chu Ka Lai Yee Kayode Ogungbenro | 2022/9 |
Effect of chronic kidney disease on the renal secretion via organic anion transporters 1/3: implications for physiologically‐based pharmacokinetic modeling and dose adjustment | Clinical Pharmacology & Therapeutics | Shawn Pei Feng Tan Daniel Scotcher Amin Rostami‐Hodjegan Aleksandra Galetin | 2022/9 |
Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease | Therapeutic Drug Monitoring | Eman El-Khateeb Rajkumar Chinnadurai Jokha Al Qassabi Daniel Scotcher Adam S Darwich | 2022/4/4 |
Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions | Clinical pharmacokinetics | Marie-Emilie Willemin Thomas K Van Der Made Ils Pijpers Lieve Dillen Annett Kunze | 2022/3 |
PBPK simulation-based evaluation of ganciclovir crystalluria risk factors: effect of renal impairment, old age, and low fluid intake | The AAPS Journal | Daniel Scotcher Aleksandra Galetin | 2022/2 |
Physiologically based pharmacokinetic modeling of transporter-mediated hepatic disposition of imaging biomarker Gadoxetate in rats | Drug Metabolism and Disposition | Masanobu Sato Kota Toshimoto Atsuko Tomaru Takashi Yoshikado Yuta Tanaka | 2018/5/1 |
Hepatic scaling factors for in vitro–in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis | Drug Metabolism and Disposition | Areti-Maria Vasilogianni Brahim Achour Daniel Scotcher Sheila Annie Peters Zubida M Al-Majdoub | 2021/7/1 |
Bringing Microphysiological Systems to Practical Use: Evaluation of transporter‐mediated DDI and Renal Clearance | The FASEB Journal | Thomas van der Made Darren Moss Daniel Scotcher Amin Rostami‐Hodjegan Aleksandra Galetin | 2021/5 |
SCALING FACTORS FOR CLEARANCE IN ADULT LIVER CIRRHOSIS. | Drug Metabolism and Disposition | Eman El-Khateeb Brahim Achour Daniel Scotcher Zubida M Al-Majdoub Varinder Athwal | 2020/9/8 |
Quantitative proteomic map of enzymes and transporters in the human kidney: stepping closer to mechanistic kidney models to define local kinetics | Clinical Pharmacology & Therapeutics | Zubida M Al‐Majdoub Daniel Scotcher Brahim Achour Jill Barber Aleksandra Galetin | 2021/11 |
Physiologically‐based pharmacokinetic modelling of creatinine‐drug interactions in the chronic kidney disease population | British Journal of Clinical Pharmacology | Shakir Atoyebi Fazila Bunglawala Nicolas Cottura Sandra Grañana‐Castillo Maiara Camotti Montanha | 2024/2/10 |
P247-indoxyl sulfate albumin-facilitated transport via renal drug transporter OAT1–translation from microfluidic in vitro system to healthy and subjects with severe kidney disease | Drug Metabolism and Pharmacokinetics | Thom van der Made Michele Fedeconstante Daniel Scotcher Amin Rostami-Hodjegan Rosalinde Masereeuw | 2020 |
A12-Mechanistic kidney models for creatinine: Relevance of OCT2 transport driving force to prediction of creatinine-drug interactions | Drug Metabolism and Pharmacokinetics | Daniel Scotcher Vikram Arya Xinning Yang Ping Zhao Lei K Zhang | 2020 |
A novel physiologically based model of creatinine renal disposition to integrate current knowledge of systems parameters and clinical observations | CPT: Pharmacometrics & Systems Pharmacology | Daniel Scotcher Vikram Arya Xinning Yang Ping Zhao Lei Zhang | 2020/6 |
Mechanistic models as framework for understanding biomarker disposition: prediction of creatinine‐drug interactions | CPT: Pharmacometrics & Systems Pharmacology | Daniel Scotcher Vikram Arya Xinning Yang Ping Zhao Lei Zhang | 2020/5 |
